{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T12:19:36Z","timestamp":1768738776242,"version":"3.49.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007077","name":"National Institute of Biomedical Innovation","doi-asserted-by":"publisher","award":["09-15"],"award-info":[{"award-number":["09-15"]}],"id":[{"id":"10.13039\/501100007077","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.bbrc.2010.08.006","type":"journal-article","created":{"date-parts":[[2010,8,7]],"date-time":"2010-08-07T04:27:53Z","timestamp":1281155273000},"page":"716-720","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease"],"prefix":"10.1016","volume":"399","author":[{"given":"Tadayasu","family":"Togawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Tsukimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Fukushige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuro","family":"Kanekura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Sakuraba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2010.08.006_b0005","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3733","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.bbrc.2010.08.006_b0010","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/318809","article-title":"A phase 1\/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies","volume":"68","author":"Eng","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbrc.2010.08.006_b0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human \u03b1-galactosidase A replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbrc.2010.08.006_b0020","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2010.08.006_b0025","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2165\/11318300-000000000-00000","article-title":"Enzyme replacement therapy for Fabry disease: a systematic review of available evidence","volume":"69","author":"Schaefer","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.bbrc.2010.08.006_b0030","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","article-title":"Fabry outcome survey investigators, Enzyme replacement therapy with agalsidase alfa in patients with Fabry\u2019s disease: an analysis of registry data","volume":"374","author":"Mehta","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.bbrc.2010.08.006_b0035","first-page":"823","article-title":"Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry disease","volume":"2","author":"Fervenza","year":"2008","journal-title":"Biologics"},{"key":"10.1016\/j.bbrc.2010.08.006_b0040","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1161\/CIRCULATIONAHA.108.841494","article-title":"Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy","volume":"119","author":"Thurberg","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.bbrc.2010.08.006_b0045","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10072-009-0211-y","article-title":"Nervous system and Fabry disease, from symptoms to diagnosis: damage evaluation and follow-up in adult patients, enzyme replacement therapy, and support therapy","volume":"31","author":"Salviati","year":"2010","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.bbrc.2010.08.006_b0050","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ymgme.2005.01.007","article-title":"Non-invasive screening method for Fabry disease by measuring globotriaosylceramide in whole urine samples using tandem mass spectrometry","volume":"85","author":"Kitagawa","year":"2005","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bbrc.2010.08.006_b0055","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10545-005-4415-x","article-title":"Monitoring enzyme replacement therapy in Fabry disease \u2013 role of urine globotriaosylceramide","volume":"28","author":"Whitfield","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.bbrc.2010.08.006_b0060","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.cca.2009.02.016","article-title":"An easy and sensitive method for determination of globotriaosylceramide (Gb3) from urinary sediment: utility for Fabry disease diagnosis and treatment monitoring","volume":"403","author":"Rozenfeld","year":"2009","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bbrc.2010.08.006_b0065","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1651-2227.2005.tb02112.x","article-title":"Is globotriaosylceramide a useful biomarker in Fabry disease?","volume":"94","author":"Young","year":"2005","journal-title":"Acta Pediatr."},{"key":"10.1016\/j.bbrc.2010.08.006_b0070","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2010.08.006_b0075","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ymgme.2010.03.020","article-title":"Plasma globotriaosylsphingosine as a biomarker of Fabry disease","volume":"100","author":"Togawa","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bbrc.2010.08.006_b0080","doi-asserted-by":"crossref","unstructured":"M.D. Sanchez-Ni\u00f1o, A.B. Sanz, S. Carrasco, M.A. Saleem, P.W. Mathieson, J.M. Valdivielso, M. Ruiz-Ortega, J. Egido, A. Ortiz, Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy, Nephrol. Dial. Transplant. 2010 May 26. [Epub ahead of print].","DOI":"10.1093\/ndt\/gfq306"},{"key":"10.1016\/j.bbrc.2010.08.006_b0085","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"\u03b1-Galactosidase A deficient mice: a model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2010.08.006_b0090","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1073\/pnas.96.11.6423","article-title":"Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice","volume":"96","author":"Ohshima","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bbrc.2010.08.006_b0095","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cca.2006.11.019","article-title":"Phospholipid storage in myocardium of a unique Japanese case of idiopathic cardiomyopathy","volume":"378","author":"Kawashima","year":"2007","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bbrc.2010.08.006_b0100","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/abbi.1994.1144","article-title":"Generation of one set of murine monoclonal antibodies specific for globo-series glycolipids: evidence for differential distribution of the glycolipids in rat small intestine","volume":"310","author":"Kotani","year":"1994","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bbrc.2010.08.006_b0105","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ajhg.2009.09.016","article-title":"Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease","volume":"85","author":"Tajima","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.bbrc.2010.08.006_b0110","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1002\/humu.21074","article-title":"Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A)","volume":"30","author":"Hwu","year":"2009","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.bbrc.2010.08.006_b0115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X1001483X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X1001483X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T14:23:14Z","timestamp":1762093394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X1001483X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0006291X1001483X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2010.08.006","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2010.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}